Deana Bell

Health tech and digital health

Deana leads independent economic validation and ROI modeling engagements for healthcare technology and digital health companies. These studies measure cost savings, changes in utilization, and the performance of value-based care programs, with work spanning care delivery innovation, specialty pharmacy, and high-cost population management. She is a member of Milliman’s Effectiveness Studies Oversight Group (ESOG), which reviews every effectiveness study the firm produces for methodological rigor and adherence to actuarial standards of practice. She has a particular interest in how AI and precision medicine affect healthcare costs and outcomes.

Health plans

Deana works with commercial insurers, Medicare Advantage plans, and Medicaid plans on bid development, pricing models, rating strategies, and risk adjustment. Her financial reporting work includes year-end statements, reserving, and actuarial opinions. She also advises plans on pharmacy contracting, including formulary design and rebates.

Providers and employers

For provider groups and employer groups, Deana performs retrospective cost and utilization reviews, benchmarking, and financial evaluations of care programs and contracting arrangements, including value-based care.

Federal and life sciences

Deana also consults for the Veterans Health Administration and for life sciences companies.